What is Opna Bio?
Opna Bio operates as a specialized biopharmaceutical enterprise headquartered in Lausanne, Switzerland, dedicated to the discovery and development of novel oncology therapeutics. The company occupies a strategic niche within the life sciences sector, focusing on high-impact molecular targets that address significant unmet needs in cancer treatment. By integrating advanced scientific methodologies with a rigorous clinical development strategy, Opna Bio aims to translate complex biological insights into viable, patient-centric medical solutions. Its market position is defined by a commitment to precision medicine and the pursuit of breakthrough therapies that offer improved outcomes for oncology patients worldwide.
How much funding has Opna Bio raised?
Opna Bio has raised a total of $38M across 1 funding round:
Series A
$38M
Series A (2022): $38M with participation from Northpond Ventures, Longitude Capital, and Menlo Ventures
Key Investors in Opna Bio
Northpond Ventures
Northpond Ventures is dedicated to advancing science and technology to create significant impacts on humanity, focusing on identifying and supporting breakthrough innovations.
Longitude Capital
Longitude Capital is a healthcare-focused venture capital firm that invests in biotechnology and medical technology, pairing sector expertise with flexible capital to help innovators scale.
Menlo Ventures
Menlo Ventures is a Menlo Park-based firm that invests in early and growth-stage technology companies, typically taking board roles and partnering with founders through multiple stages of scale.
What's next for Opna Bio?
Looking ahead, the strategic deployment of the recent capital will likely focus on accelerating the progression of lead candidates through preclinical and clinical milestones. Opna Bio is expected to prioritize the scaling of its research capabilities and the potential expansion of its intellectual property portfolio. As the company matures, the focus will shift toward establishing strategic partnerships with larger pharmaceutical entities to facilitate late-stage development and commercialization. This growth phase will be characterized by a heightened emphasis on regulatory compliance, clinical trial execution, and the continued refinement of its therapeutic platform to ensure long-term sustainability and market competitiveness.
See full Opna Bio company page
